We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
76
Tango Therapeutics
TNGX
$4.03B
$8.21M 0.04%
750,000
– –
KYNB
77
Kyntra Bio
KYNB
$30.4M
$8.18M 0.04%
+23,206
New +$7.23M
EWTX icon
78
Edgewise Therapeutics
EWTX
$4.8B
$7.64M 0.04%
500,000
– –
CBAY
79
DELISTED
Cymabay Therapeutics
CBAY
$7.34M 0.04%
2,170,464
– –
MGNX icon
80
MacroGenics
MGNX
$261M
$7.1M 0.03%
442,579
– –
ITOS
81
DELISTED
iTeos Therapeutics
ITOS
$7M 0.03%
150,346
– –
NVAX icon
82
Novavax
NVAX
$1.47B
$6.89M 0.03%
48,168
-60,588
-56% -$10.4M
ALLK
83
DELISTED
Allakos
ALLK
$6.88M 0.03%
703,050
– –
TCRX icon
84
TScan Therapeutics
TCRX
$52.8M
$6.41M 0.03%
1,425,000
– –
RETA
85
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.91M 0.03%
223,976
– –
RVMD icon
86
Revolution Medicines
RVMD
$44.9B
$5.59M 0.03%
222,222
– –
HRMY icon
87
Harmony Biosciences
HRMY
$2.22B
$5.27M 0.03%
123,600
– –
NGM
88
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5.17M 0.03%
291,801
– –
ALEC icon
89
Alector
ALEC
$264M
$4.94M 0.02%
239,228
– –
ATYR
90
aTyr Pharma
ATYR
$49.2M
$4.67M 0.02%
625,000
– –
KURA icon
91
Kura Oncology
KURA
$1.06B
$4.26M 0.02%
304,158
– –
DNLI icon
92
Denali Therapeutics
DNLI
$3.98B
$3.96M 0.02%
88,738
– –
BMEA icon
93
Biomea Fusion
BMEA
$99.3M
$3.91M 0.02%
524,617
– –
TCRR
94
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.51M 0.02%
753,064
+576,603
+327% +$3.6M
GTH
95
DELISTED
Genetron Holdings Limited ADS
GTH
$2.78M 0.01%
151,769
– –
CABA icon
96
Cabaletta Bio
CABA
$531M
$2.51M 0.01%
662,063
– –
AKRO
97
DELISTED
Akero Therapeutics
AKRO
$2.5M 0.01%
118,378
– –
VINC
98
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$2.46M 0.01%
12,069
– –
ALBO
99
DELISTED
Albireo Pharma Inc
ALBO
$2.43M 0.01%
104,521
-307,945
-75% -$8.19M
SNDX icon
100
Syndax Pharmaceuticals
SNDX
$1.75B
$2.42M 0.01%
110,729
– –
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2021 Portfolio in Review

As of Q4 2021, Julian Baker held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Julian Baker added most to Incyte in Q4 2021, an estimated $108M increase.
  • Julian Baker's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Julian Baker fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Julian Baker's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Julian Baker opened 5 new positions and closed 5 in Q4 2021.
  • Julian Baker's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.